Clinical trial NCT02712320: Open-Label Safety Extension Study in Patients Who Have Previously Participated and Have Benefited From LMIS 50 mg
Official title: An Open-Label, Single-Arm Study of the Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate for Injectable Suspension (LMIS 50 mg) in Subjects With Advanced Prostate Carcinoma - SAFETY EXTENSION
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Prostatic Neoplasms
Keywords: Prostate Neoplasm Cancer Carcinoma
Safety Extension
Lead sponsor: Foresee Pharmaceuticals Co., Ltd.
Sponsor class: INDUSTRY
Collaborators: name: QPS-Qualitix
First posted: 2016-03-18
Enrollment: 30
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a safety extension of up to 12 months of additional treatment with LMIS 50 mg after the subject has completed 12 months of treatment under Protocol FP01C-13-001 and remain eligible for continued treatment with androgen deprivation therapy. Subjects participating in Protocol FP01C-13-001-EX will be followed for safety only.

Detailed description: This is a multi-center, open-label, single-arm safety extension study. After completing 12 months of treatment with LMIS 50 mg under Protocol FP01C-13-001 (with last dose under Protocol FP01C-13-001 approximately 6 months prior to Day 0 or Protocol FP01C-13-001-EX) and providing a written informed consent, subjects will be screened against baseline inclusion/exclusion criteria necessary for study eligibility. Eligible subjects will receive LMIS 50 mg from the prefilled syringes (without dilution or other mixing) in up to two single subcutaneous injections given 6 months apart.

Eligibility criteria: Inclusion Criteria:

1. Complete 12 months of treatment with LMIS 50 mg under Protocol FP01C-13-001. If a subject wishes to enter the Extension study after more than 28 days following his end of study visit for Protocol FP01C-13-001, his serum testosterone level should be repeated at the screening visit to confirm that his castrate-level testosterone has been maintained.
2. Laboratory values

   * Absolute neutrophil count ≥ 1,500 cells/µL
   * Platelets≥100,000 cells/µL
   * Hemoglobin ≥ 10 gm/dL
   * Total bilirubin ≤ 1.5 × upper limit of normal (ULN)
   * Aspartate Transaminase (AST/SGOT) ≤ 2.5 × ULN
   * Alanine Aminotransferase (ALT/SGPT) ≤ 2.5 × ULN
   * Serum creatinine ≤ 1.5 mg/dL
   * Lipid profile within acceptable range according to investigator's opinion
   * Serum glucose within acceptable range according to investigator's opinion
   * HgbA1c within acceptable range according to investigator's opinion
   * Clinical chemistries (K, Na, Mg, Ca and P) within acceptable range according to investigator's judgment
   * Urinalysis within normal range according to the investigator's judgment
3. Agree to use male contraceptive methods during study trial
4. In the Investigator's opinion, the ability to understand the nature of the study and any hazards of participation, and to communicate satisfactorily with the Investigator and to participate in, and to comply with, the requirements of the entire protocol
5. All aspects of the protocol explained and written informed consent obtained \*If the patient completed 12 months of treatment with LMIS 50 mg more than 28 days prior to entering the Extension study, the Eastern Cooperative Oncology Group (ECOG), Physical Examination (PE), ECG, laboratory and Prostate Specific Antigen (PSA) tests should be repeated.

If the patient has completed 12 months of treatment with LMIS 50 mg under Protocol FP01C-13-001 within the last 28 days, they will be allowed to enter the Extension study without repeating the testosterone measurements, ECG, PE, laboratory and the PSA tests

Exclusion Criteria:

1. Receipt of chemotherapy, immunotherapy, cryotherapy, radiotherapy, or anti-androgen therapy other than LMIS 50 mg under Protocol FP01C-13-001 for treatment of carcinoma of the prostate during the subject's participation in Protocol FP01C-13-001. Radiation for pain control will be allowed during the study.
2. Receipt of any Luteinizing Hormone-releasing Hormone (LHRH) suppressive therapy within 6 months of Screening Visit other than LMIS 50 mg under Protocol FP01C-13-001
3. Subject has used prohibited treatments as listed in the Section 8.2 during participation in Protocol FP01C-13-001.
4. Any pathological event, clinical adverse event, or any change in the subject's status at the end of FP01C-13-001 giving indication to the investigator that further participation in the study may not be the best interest of the subject
5. Investigator considers that it is no longer feasible for the subject to be included in a study of LMIS 50 mg
6. Subjects with persistent, non-castrate testosterone levels judged by the investigator
7. Uncontrolled intercurrent illness that would jeopardize the subject's safety, interfere with the objectives of the protocol, or limit the subject's compliance with study requirements, as determined by the Investigator in consultation with the Sponsor

Primary outcomes:
measure: Number of Participants With Adverse Events
timeFrame: Up to 48 weeks
measure: Evaluate the Effect of LMIS 50 mg on Cardiovascular Function
timeFrame: Up to 48 weeks
measure: Laboratory Assessments - Hematology
timeFrame: 48 weeks
measure: Laboratory Assessments - Biochemistry
timeFrame: 48 weeks
measure: Laboratory Assessments - Urinalysis
timeFrame: 48 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Homewood
country: United States
facility: Urology Centers of Alabama
state: Alabama
city: San Diego
country: United States
facility: Genesis Research, LLC
state: California
city: Meridian
country: United States
facility: Idaho Urologic Institute - Meridian
state: Idaho
city: Lawrenceville
country: United States
facility: AdvanceMed Research
state: New Jersey
city: Concord
country: United States
facility: Carolina Clinical Trials, LLC
state: North Carolina
city: Myrtle Beach
country: United States
facility: Carolina Urologic Research Center
state: South Carolina
city: Burien
country: United States
facility: Seattle Urology Research Center
state: Washington
Study officials:
affiliation: Foresee Pharmaceuticals Co., Ltd.
name: John Mao, Ph.D.
role: STUDY_DIRECTOR
References: